Mechanisms of aortic stenosis

Journal of Cardiology

Volumn 71, Issue 3, 2018, Pages 215-220

  Akahori, Hirokuni ^a   Tsujino, Takeshi ^a   Masuyama, Tohru ^a   Ishihara, Masaharu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Aortic stenosis; Intraleaflet hemorrhage; Osteogenic differentiation

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; HYPOXIA INDUCIBLE FACTOR; I KAPPA B; INTERMEDIN; LIPID; TRANSCRIPTION FACTOR RUNX2; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BMP2 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANGIOGENESIS; AORTIC STENOSIS; AORTIC VALVE; BLEEDING; CELL DIFFERENTIATION; HISTOLOGY; HOMEOBOX; HUMAN; INFLAMMATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING; AORTIC VALVE STENOSIS; BONE DEVELOPMENT; CALCINOSIS; COMPLICATION; DISEASE EXACERBATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AORTIC VALVE; AORTIC VALVE STENOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE MORPHOGENETIC PROTEIN 2; CALCINOSIS; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 85039458231     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2017.11.007     Document Type: Review

References (82)

1. Lindroos, M., Kupari, M., Heikkila, J., Tilvis, R., Prevalence of aortic valve abnormalities in the elderly: an echocardiography study of a random population sample. J Am Coll Cardiol 21 (1993), 1220–1225.
2. Iung, B., Baron, G., Butchart, E.G., Delahaye, F., Gohlke-Barwolf, C., Levang, O.W., et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 24 (2003), 1231–1243.
3. Goldbarg, S.H., Elmariah, S., Miller, M.A., Fuster, V., Insights into degenerative aortic valve disease. J Am Coll Cardiol 50 (2007), 1205–1213.
4. Lindblom, D., Lindblom, U., Qvist, J., Lundstrom, H., Long-term relative survival rates after heart valve replacement. J Am Coll Cardiol 15 (1990), 566–573.
5. Connolly, H.M., Oh, J.K., Orszulak, T.A., Osborn, S.L., Roger, V.L., Hodge, D.O., et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation 95 (1997), 2395–2400.
6. Nishimura, R.A., Otto, C.M., Bonow, R.O., Carabello, B.A., Erwin, J.P. 3rd, Guyton, R.A., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
7. Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M.J., Barón-Esquivias, G., Baumgartner, H., et al. Guidelines on the management of valvular heart disease (version 2012). Joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 33 (2012), 2451–2496.
8. Roberts, W.C., Ko, J.M., Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 111 (2005), 920–925.
9. Bosse, Y., Mathieu, P., Pibarot, P., Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. J Am Coll Cardiol 51 (2008), 1327–1336.
10. Michelena, H.I., Khanna, A.D., Mahoney, D., Margaryan, E., Topilsky, Y., Suri, R.M., et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA 306 (2011), 1104–1112.
11. Michelena, H.I., Prakash, S.K., Della Corte, A., Bissell, M.M., Anavekar, N., Mathieu, P., et al. Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the international bicuspid aortic valve consortium (BAVCon). Circulation 129 (2014), 2691–2704.
12. Eveborn, G.W., Schirmer, H., Heggelund, G., Lunde, P., Rasmussen, K., The evolving epidemiology of valvular aortic stenosis. The Tromso Study. Heart 99 (2013), 396–400.
13. Lindroos, M., Kupari, M., Heikkila, J., Tilvis, R., Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21 (1993), 1220–1225.
14. Danielsen, R., Aspelund, T., Harris, T.B., Gudnason, V., The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavik study. Int J Cardiol 176 (2014), 916–922.
15. Agmon, Y., Khandheria, B.K., Meissner, I., Sicks, J.R., O'Fallon, W.M., Wiebers, D.O., et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 38 (2001), 827–834.
16. Deutscher, S., Rockette, H.E., Krishnaswami, V., Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 37 (1984), 407–415.
17. Lindroos, M., Kupari, M., Valvanne, J., Strandberg, T., Heikkilä, J., Tilvis, R., Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15 (1994), 865–870.
18. Mohler, E.R., Sheridan, M.J., Nichols, R., Harvey, W.P., Waller, B.F., Development and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. Clin Cardiol 14 (1991), 995–999.
19. Pohle, K., Otte, M., Mäffert, R., Ropers, D., Schmid, M., Daniel, W.G., et al. Association of cardiovascular risk factors to aortic valve calcification as quantified by electron beam computed tomography. Mayo Clin Proc 79 (2004), 1242–1246.
20. Stewart, B.F., Siscovick, D., Lind, B.K., Gardin, J.M., Gottdiener, J.S., Smith, V.E., et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 29 (1997), 630–634.
21. Naito, Y., Tsujino, T., Akahori, H., Ohyanagi, M., Mitsuno, M., Miyamoto, Y., et al. Augmented cannabinoid receptors expression in human aortic valve stenosis. Int J Cardiol 145 (2010), 535–537.
22. Naito, Y., Tsujino, T., Akahori, H., Matsumoto, M., Ohyanagi, M., Mitsuno, M., et al. Increased serum neopterin in patients with nonrheumatic aortic valve stenosis. Int J Cardiol 145 (2010), 360–361.
23. Naito, Y., Tsujino, T., Wakabayashi, K., Matsumoto, M., Ohyanagi, M., Mitsuno, M., et al. Increased interleukin-18 expression in nonrheumatic aortic valve stenosis. Int J Cardiol 144 (2010), 260–263.
24. Olsson, M., Thyberg, J., Nilsson, J., Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 (1999), 1218–1222.
25. Soini, Y., Salo, T., Satta, J., Angiogenesis is involved in the pathogenesis of nonrheumatic aortic valve stenosis. Hum Pathol 34 (2003), 756–763.
26. Otto, C.M., Kuusisto, J., Reichenbach, D.D., Gown, A.M., O'Brien, K.D., Characterization of the early lesion of degenerative valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994), 844–853.
27. Moura, L.M., Ramos, S.F., Zamorano, J.L., Barros, I.M., Azevedo, L.F., Rocha-Gonçalves, F., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007), 554–561.
28. Cowell, S.J., Newby, D.E., Prescott, R.J., Bloomfield, P., Reid, J., Northridge, D.B., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005), 2389–2397.
29. Rossebø, A.B., Pedersen, T.R., Boman, K., Brudi, P., Chambers, J.B., Egstrup, K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359 (2008), 1343–1356.
30. Harken, D.E., Soroff, H.S., Taylor, W.J., Lefemin, A.A., Gupta, S.K., Lunzer, S., Partial and complete prostheses in aortic insufficiency. J Thorac Cardiovasc Surg 40 (1960), 744–762.
31. Lee, R., Li, S., Rankin, J.S., O'Brien, S.M., Gammie, J.S., Peterson, E.D., et al. Fifteen-year outcome trends for valve surgery in North America. Ann Thorac Surg 91 (2011), 677–684.
32. Brown, J.M., O'Brien, S.M., Wu, C., Sikora, J.A., Griffith, B.P., Gammie, J.S., Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg 137 (2009), 82–90.
33. Ambler, G., Omar, R.Z., Royston, P., Kinsman, R., Keogh, B.E., Taylor, K.M., Generic, simple risk stratification model for heart valve surgery. Circulation 112 (2005), 224–231.
34. Ashikhmina, E.A., Schaff, H.V., Dearani, J.A., Sundt, T.M. 3rd, Suri, R.M., Park, S.J., et al. Aortic valve replacement in the elderly: determinants of late outcome. Circulation 124 (2011), 1070–1078.
35. Iung, B., Cachier, A., Baron, G., Messika-Zeitoun, D., Delahaye, F., Tornos, P., et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. Eur Heart J 26 (2005), 2714–2720.
36. Bach, D.S., Siao, D., Girard, S.E., Duvernoy, C., McCallister, B.D. Jr., Gualano, S.K., Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes 2 (2009), 533–539.
37. Leon, M.B., Smith, C.R., Mack, M., Miller, D.C., Moses, J.W., Svensson, L.G., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. Randomized clinical trial that demonstrates the major superiority of transcatheter aortic valve replacement compared to conservative management in patients who can not undergo surgical aortic valve replacement. N Engl J Med 363 (2010), 1597–1607.
38. Smith, C.R., Leon, M.B., Mack, M.J., Miller, D.C., Moses, J.W., Svensson, L.G., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
39. Adams, D.H., Popma, J.J., Reardon, M.J., Yakubov, S.J., Coselli, J.S., Deeb, G.M., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. Randomized clinical trial that demonstrates a superiority of transcatheter aortic valve replacement compared to surgical aortic valve replacement in patients with high surgical risk. N Engl J Med 370 (2014), 1790–1798.
40. Kapadia, S.R., Leon, M.B., Makkar, R.R., Tuzcu, E.M., Svensson, L.G., Kodali, S., et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2485–2491.
41. Mack, M.J., Leon, M.B., Smith, C.R., Miller, D.C., Moses, J.W., Tuzcu, E.M., et al. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 385 (2015), 2477–2484.
42. Popma, J.J., Adams, D.H., Reardon, M.J., Yakubov, S.J., Kleiman, N.S., Heimansohn, D., et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63 (2014), 1972–1981.
43. Taylor, P.M., Allen, S.P., Yacoub, M.H., Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J Heart Valve Dis 9 (2000), 150–158.
44. Latif, N., Sarathchandra, P., Chester, A.H., Yacoub, M.H., Expression of smooth muscle cell markers and co-activators in calcified aortic valves. Eur Heart J 36 (2015), 1335–1345.
45. Waltenberger, J., Lundin, L., Oberg, K., Wilander, E., Miyazono, K., Heldin, C.H., et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 142 (1993), 71–78.
46. Sanderson, N., Factor, V., Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 92 (1995), 2572–2576.
47. Kopp, J.B., Factor, V.M., Mozes, M., Nagy, P., Sanderson, N., Böttinger, E.P., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Investig 74 (1996), 991–1003.
48. Jones, P.L., Jones, F.S., Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19 (2000), 581–596.
49. Caira, F.C., Stock, S.R., Gleason, T.G., McGee, E.C., Huang, J., Bonow, R.O., et al. Human degenerative valve disease is associated with upregulation of low-density lipoprotein receptor related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47 (2006), 1707–1712.
50. Parhami, F., Basseri, B., Hwang, J., Tintut, Y., Demer, L.L., High-density lipoprotein regulates calcification of vascular cells. Circ Res 91 (2002), 570–576.
51. Parhami, F., Morrow, A.D., Balucan, J., Leitinger, N., Watson, A.D., Tintut, Y., et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 17 (1997), 680–687.
52. Yoshioka, M., Yuasa, S., Matsumura, K., Kimura, K., Shiomi, T., Kimura, N., et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 12 (2006), 1151–1159.
53. Hiraki, Y., Molecular cloning of a novel cartilage specific functional matrix, chondromodulin-I, and its role in endochondral bone formation. Seikagaku 63 (1991), 1449–1454.
54. Saito, T., Fukai, A., Mabuchi, A., Ikeda, T., Yano, F., Ohba, S., et al. Transcriptional regulation of endochondral ossification by HIF-2 alpha during skeletal growth and osteoarthritis development. Nat Med 16 (2010), 678–686.
55. Abdelbaky, A., Corsini, E., Figueroa, A.L., Subramanian, S., Fontanez, S., Emami, H., et al. Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET/CT study. Atherosclerosis 238 (2015), 165–172.
56. O'Brien, K.D., Reichenbach, D.D., Marcovina, S.M., Kuusisto, J., Alpers, C.E., Otto, C.M., Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16 (1996), 523–532.
57. Su, X., Ao, L., Shi, Y., Johnson, T.R., Fullerton, D.A., Meng, X., Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem 286 (2011), 12213–12220.
58. Shao, J.S., Cheng, S.L., Pingsterhaus, J.M., Charlton-Kachigian, N., Loewy, A.P., Towler, D.A., Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Investig 115 (2005), 1210–1220.
59. Rajamannan, N.M., Subramaniam, M., Caira, F., Stock, S.R., Spelsberg, T.C., Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112:9 Suppl. (2005), I229–I234.
60. Rajamannan, N.M., Subramaniam, M., Springett, M., Sebo, T.C., Niekrasz, M., McConnell, J.P., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105 (2002), 2660–2665.
61. Rajamannan, N.M., Subramaniam, M., Rickard, D., Stock, S.R., Donovan, J., Springett, M., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 (2003), 2181–2184.
62. Arishiro, K., Hoshiga, M., Negoro, N., Okabe, T., Ishihara, T., Hanafusa, T., Angiotensin receptor 1 blocker reduces atherosclerotic changes of aortic valve in hypercholesterolemic rabbit model. J Am Coll Cardiol 47 (2006), 284A–285A.
63. Zhang, M., Liu, X., Zhang, X., Song, Z., Han, L., He, Y., et al. MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells. J Thorac Cardiovasc Surg 147 (2014), 1073–1080.
64. Mohty, D., Pibarot, P., Després, J.P., Côté, C., Arsenault, B., Cartier, A., et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28 (2008), 187–193.
65. Côté, C., Pibarot, P., Després, J.P., Mohty, D., Cartier, A., Arsenault, B.J., et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 94 (2008), 1175–1180.
66. Johnson, R.C., Leopold, J.A., Loscalzo, J., Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 99 (2006), 1044–1059.
67. Akahori, H., Tsujino, T., Naito, Y., Matsumoto, M., Lee-Kawabata, M., Ohyanagi, M., et al. Intraleaflet haemorrhage is associated with rapid progression of degenerative aortic valve stenosis. Eur Heart J 32 (2011), 888–896.
68. Coté, N., Mahmut, A., Bosse, Y., Couture, C., Pagé, S., Trahan, S., et al. Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation 36 (2013), 573–581.
69. Venardos, N., Nadlonek, N.A., Zhan, Q., Weyant, M.J., Reece, T.B., Meng, X., et al. Aortic valve calcification is mediated by a differential response of aortic valve interstitial cells to inflammation. J Surg Res 190 (2014), 1–8.
70. West, X.Z., Malinin, N.L., Merkulova, A.A., Tischenko, M., Kerr, B.A., Borden, E.C., et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467 (2010), 972–976.
71. El Husseini, D., Boulanger, M.C., Mahmut, A., Bouchareb, R., Laflamme, M.H., Fournier, D., et al. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol 72 (2014), 146–156.
72. Kaden, J.J., Bickelhaupt, S., Grobholz, R., Haase, K.K., Sarikoç, A., Kiliç, R., et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004), 57–66.
73. Hammon, J.W. Jr., O'Sullivan, M.J., Oury, J., Fosburg, R.G., Allograft cardiac valves. A view through the scanning electron microscope. J Thorac Cardiovasc Surg 68 (1974), 352–360.
74. Rajamannan, N.M., Nealis, T.B., Subramaniam, M., Pandya, S., Stock, S.R., Ignatiev, C.I., et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 111 (2005), 3296–3301.
75. Doyle, B., Caplice, N., Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49 (2007), 2073–2080.
76. Sluimer, J.C., Daemen, M.J., Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 218 (2009), 7–29.
77. Takaya, N., Yuan, C., Chu, B., Saam, T., Polissar, N.L., Jarvik, G.P., et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111 (2005), 2768–2775.
78. Moreno, P.R., Purushothaman, K.R., Fuster, V., Echeverri, D., Truszczynska, H., Sharma, S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 (2004), 2032–2038.
79. Virmani, R., Kolodgie, F.D., Burke, A.P., Finn, A.V., Gold, H.K., Tulenko, T.N., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25 (2005), 2054–2061.
80. Otto, C.M., Kuusisto, J., Reichenbach, D.D., Gown, A.M., O'Brien, K.D., Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 (1994), 844–853.
81. De Martin, R., Hoeth, M., Hofer-Warbinek, R., Schmid, J.A., The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 20 (2000), e83–e88.
82. Yunoki, K., Naruko, T., Komatsu, R., Ehara, S., Shirai, N., Sugioka, K., et al. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes. Eur Heart J 30 (2009), 1844–1852.